Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Jianshu Wei, Yang Liu, Chunmeng Wang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

T cells in health and disease
Lina Sun, Yanhong Su, Anjun Jiao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 355
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Xiaomin Zhang, Lingling Zhu, Hui Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 209
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
Xinyi Xiao, Shengkang Huang, Sifei Chen, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 157
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Zinaida Good, Jay Y. Spiegel, Bita Sahaf, et al.
Nature Medicine (2022) Vol. 28, Iss. 9, pp. 1860-1871
Open Access | Times Cited: 148
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
Kai Rejeski, Ariel Perez Perez, Gloria Iacoboni, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 5, pp. e004475-e004475
Open Access | Times Cited: 110
Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma
Xiufeng Zheng, Xun Liu, Yanna Lei, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 83
Applications of synthetic biology in medical and pharmaceutical fields
Xu Yan, Xu Liu, Cuihuan Zhao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 67
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Lu Tang, Zhongpei Huang, Heng Mei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 56
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Deep Shah, Brian W. Soper, Lindsay S. Shopland
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 41
Potential drug targets of SARS-CoV-2: From genomics to therapeutics
Anas Shamsi, Taj Mohammad, Saleha Anwar, et al.
International Journal of Biological Macromolecules (2021) Vol. 177, pp. 1-9
Open Access | Times Cited: 96
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
Paolo F. Caimi, Gabriela Pacheco Sánchez, Ashish Sharma, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 87
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
Weidong Han, Yao Wang, Yang Liu, et al.
Leukemia (2021) Vol. 36, Iss. 1, pp. 189-196
Open Access | Times Cited: 70
Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma
Xiaolan Shi, Lingzhi Yan, Jingjing Shang, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 5, pp. 537-547
Open Access | Times Cited: 57
Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications
Caio Raony Farina Silveira, Amanda Cristina Corveloni, Sâmia Rigotto Caruso, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 46
New Strategy for Promoting Vascularization in Tumor Spheroids in a Microfluidic Assay
Zhengpeng Wan, Marie Floryan, Mark F. Coughlin, et al.
Advanced Healthcare Materials (2022) Vol. 12, Iss. 14
Open Access | Times Cited: 46
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
Kai Rejeski, Ariel Perez Perez, Gloria Iacoboni, et al.
Science Advances (2023) Vol. 9, Iss. 38
Open Access | Times Cited: 33
Dose fractionation of CAR-T cells. A systematic review of clinical outcomes
Matthew J. Frigault, Anand Rotte, Ayub Ansari, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 27
Efficacy and Safety of CART Cell Therapy in Aggressive B‐Cell Lymphomas Involving the Gastrointestinal Tract
Lixia Ma, Yimeng Dou, Rui Liu, et al.
Cancer Reports (2025) Vol. 8, Iss. 1
Open Access | Times Cited: 1
Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
Jiaying Wu, Fankai Meng, Yang Cao, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 7
Open Access | Times Cited: 46
Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer
Anat Aharon, Galit Horn, Tali Hana Bar-Lev, et al.
Human Gene Therapy (2021) Vol. 32, Iss. 19-20, pp. 1224-1241
Closed Access | Times Cited: 43
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
Xiao Wang, Xuejiao Yang, Xiang Yuan, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 36
Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology
Timothy Qi, Kyle McGrath, Raghuveer Ranganathan, et al.
Advanced Drug Delivery Reviews (2022) Vol. 188, pp. 114421-114421
Open Access | Times Cited: 31
Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles
Donghyeon Jo, Shelby Kaczmarek, Oksu Shin, et al.
Molecular Therapy — Methods & Clinical Development (2023) Vol. 29, pp. 173-184
Open Access | Times Cited: 18
Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma
Hanqi Wang, Ruxing Fu, Qi‐Wen Man, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 6, pp. 2173-2173
Open Access | Times Cited: 17
Direct comparison of canine and human immune responses using transcriptomic and functional analyses
Lyndah Chow, William H. Wheat, Dominique Ramirez, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top